Reversal of Aberrant Cancer Methylome and Transcriptome Upon Direct Reprogramming of Lung Cancer Cells

Overview

Journal Sci Rep

Specialty Science

Date 2012 Aug 23

PMID 22912920

Citations 24

Authors

Dashayini Mahalingam

Chiou Mee Kong

Jason Lai

Ling Lee Tay

Henry Yang

Xueying Wang

Affiliations

Soon will be listed here.

Abstract

Recent reports on direct reprogramming of cancer cells (iPCs) which results in reduced tumorigenic potential has attributed the importance of epigenetics in tumorigenesis, but lacked genome-wide analysis. Here we describe successful generation of iPCs from non-small cell lung cancer (NSCLC) cell lines. Following reprogramming, they resembled embryonic stem and induced pluripotent stem cells in pluripotency markers expression, gene expression patterns and in vitro differentiation ability. Genome-wide methylation analysis revealed that aberrantly methylated promoters which were mostly developmental-associated genes and tumor suppressors; as well as commonly upregulated genes in NSCLC i.e. KRT19 and S100P were reversed in iPCs upon reprogramming. Also, the reversal of oncogenes and tumor suppressors status were partially explainable by DNA methylation. These findings suggest that DNA methylation patterns explain the downstream transcriptional effects, which potentially caused the reduced tumorigenicity in iPCs, thus providing evidence that reprogramming reverses the aberrantly dysregulated genes in NSCLC both epigenetically and transcriptionally.

Citing Articles

Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells.

Lin Y, Ku C, Wuputra K, Liu C, Wu D, Satou M Int J Mol Sci. 2024; 25(10).

PMID: 38791215 PMC: 11120835. DOI: 10.3390/ijms25105177.

Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors.

He R, Weng Z, Liu Y, Li B, Wang W, Meng W Stem Cell Rev Rep. 2023; 19(8):2557-2575.

PMID: 37755647 PMC: 10661832. DOI: 10.1007/s12015-023-10633-y.

Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance.

Castro-Perez E, Singh M, Sadangi S, Mela-Sanchez C, Setaluri V Pigment Cell Melanoma Res. 2023; 36(5):330-347.

PMID: 37132530 PMC: 10524512. DOI: 10.1111/pcmr.13092.

Cancer cells as a new source of induced pluripotent stem cells.

Shamsian A, Sahebnasagh R, Norouzy A, Hussein S, Ghahremani M, Azizi Z Stem Cell Res Ther. 2022; 13(1):459.

PMID: 36064437 PMC: 9446809. DOI: 10.1186/s13287-022-03145-y.

Revisiting Epithelial Carcinogenesis.

Mendez-Lopez L Int J Mol Sci. 2022; 23(13).

PMID: 35806442 PMC: 9267463. DOI: 10.3390/ijms23137437.

References

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

Camilo R, Capelozzi V, Siqueira S, Bernardi F . Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006; 37(5):542-6. DOI: 10.1016/j.humpath.2005.12.019. View

Devine M, Ryten M, Vodicka P, Thomson A, Burdon T, Houlden H . Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun. 2011; 2:440. PMC: 3265381. DOI: 10.1038/ncomms1453. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Helman E, Naxerova K, Kohane I . DNA hypermethylation in lung cancer is targeted at differentiation-associated genes. Oncogene. 2011; 31(9):1181-8. DOI: 10.1038/onc.2011.307. View

Higgins M, Claremont M, Major J, Sander C, Lash A . CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res. 2006; 35(Database issue):D721-6. PMC: 1781153. DOI: 10.1093/nar/gkl811. View

Keeley E, Mehrad B, Strieter R . CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 2010; 106:91-111. PMC: 3069502. DOI: 10.1016/S0065-230X(10)06003-3. View

Arumugam T, Logsdon C . S100P: a novel therapeutic target for cancer. Amino Acids. 2010; 41(4):893-9. PMC: 4041611. DOI: 10.1007/s00726-010-0496-4. View

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

10.

Chin M, Mason M, Xie W, Volinia S, Singer M, Peterson C . Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009; 5(1):111-23. PMC: 3448781. DOI: 10.1016/j.stem.2009.06.008. View

11.

Wang K, Liu N, Radulovich N, Wigle D, Johnston M, Shepherd F . Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene. 2002; 21(49):7598-604. DOI: 10.1038/sj.onc.1205953. View

12.

Hirashima T, Takada M, Komiya T, Nitta T, Masashi K, Masuda N . Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res. 1999; 18(6B):4713-6. View

13.

Esteller M . Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16 Spec No 1:R50-9. DOI: 10.1093/hmg/ddm018. View

14.

Liu H, Kho A, Kohane I, Sun Y . Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med. 2006; 3(7):e232. PMC: 1483910. DOI: 10.1371/journal.pmed.0030232. View

15.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

16.

Allegrucci C, Rushton M, Dixon J, Sottile V, Shah M, Kumari R . Epigenetic reprogramming of breast cancer cells with oocyte extracts. Mol Cancer. 2011; 10(1):7. PMC: 3034708. DOI: 10.1186/1476-4598-10-7. View

17.

Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L . Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004; 18(15):1875-85. PMC: 517407. DOI: 10.1101/gad.1213504. View

18.

Deaton A, Bird A . CpG islands and the regulation of transcription. Genes Dev. 2011; 25(10):1010-22. PMC: 3093116. DOI: 10.1101/gad.2037511. View

19.

Fingleton B . Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets. 2003; 7(3):385-97. DOI: 10.1517/14728222.7.3.385. View

20.

Jarmalaite S, Laurinaviciene A, Tverkuviene J, Kalinauskaite N, Petroska D, Bohling T . Tumor suppressor gene ZAC/PLAGL1: altered expression and loss of the nonimprinted allele in pheochromocytomas. Cancer Genet. 2011; 204(7):398-404. DOI: 10.1016/j.cancergen.2011.07.002. View